LBI-HTA - Publications - Search - Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia

Warmuth, M. (2009): Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 04.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
214Kb
Abstract

Rituximab, an anti-CD20 monoclonal antibody, has been approved for the treatment of various non-Hodgkin lymphomas for years. Recently two phase III trials assessed the benefit of adding rituximab to common chemotherapy regimens for the first- and second-line treatment of chronic lymphocytic leukaemia (CLL). Although both trials showed a significantly increased complete remission rate and progression-free survival in the intervention compared to the control group, there was no difference in overall survival between the two groups. Because rituximab is an add-on to existing treatment regimens and CLL is on the rise in Austria due to an ageing population, the financial impact of adding rituximab will be substantial.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:Rituximab, Rituxan, MabThera, monoclonal antibody, CLL, NHL, Oncology
Subjects:QZ Pathology > QZ 200-380 Neoplasms.Cysts
WH Hemic and lymphatic systems
Language:English
Series Name:DSD: Horizon Scanning in Oncology 04
Deposited on:02 Nov 2009 16:20
Last Modified:02 Nov 2009 16:20

Repository Staff Only: item control page